Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.61 |
| ▸ | ITGAV | P06756 | 20/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8600097 | 0.95 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL18135224 | 0.95 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL12372085 | 0.94 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL14440961 | 0.94 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL14039898 | 0.91 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL26473438 | 0.91 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL13703192 | 0.90 | ITGB3 (0.57) | ITGB3ITGAVITGA2B | |
| SCHEMBL14015526 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL14460008 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2B | |
| SCHEMBL8312725 | 0.89 | ITGB3 (0.55) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090317475-A1 | COMBINATION ANTITUMOR THERAPIES | KEREOS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090317475-A1 | COMBINATION ANTITUMOR THERAPIES | KEREOS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080274056-A1 | NANOPARTICLE DELIVERY SYSTEMS FOR MEMBRANE-INTEGRATING PEPTIDES | KEREOS, INC. | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317475-A1 | COMBINATION ANTITUMOR THERAPIES | FLT4, HDGF, KDR | ITGB3 1166/4885ITGAV 1530/4885ITGA2B 1439/4885 |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | ITGB3 857/4885ITGAV 379/4885ITGA2B 736/4885 |
| US-20080274056-A1 | NANOPARTICLE DELIVERY SYSTEMS FOR MEMBRANE-INTEGRATING PEPTIDES | LNPEP, HM13, HPN | ITGB3 1563/4885ITGAV 1664/4885ITGA2B 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.